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At a Glance Commentary 
Scientific Knowledge on the Subject 
Periconceptional folic acid supplement use at 400 µg per day is internationally recommended to 
prevent neural tube defects and mandatory folic acid food fortification has been implemented in 
some countries to better target women of reproductive age at the population level. In animal 
models and human studies, supplementation with folic acid and other methyl donors during 
pregnancy alters the offspring epigenome which can influence health outcomes in offspring. 
Various observational studies have examined the association between maternal folate exposure 
and children’s respiratory outcomes. This literature has been summarized in systematic reviews 
as inconclusive with limitations from methodological issues, including possible differential loss 
to follow-up. Few studies have assessed total folate intake from both food and supplements in 
relation to asthma at school age when the diagnosis is more certain than at preschool age.  
What This Study Adds to the Field 
Virtually complete follow-up of children was enabled by linkage to the Norwegian Prescription 
Database. Folate intake from both food and supplements was assessed with a questionnaire 
validated against maternal plasma folate measurements. Our findings suggest that pregnant 
women who take supplements containing folic acid, at or above the recommended dose, 
combined with a diet rich in folate, reach a total folate intake level associated with a slightly 
increased risk of children’s asthma. 
Online data supplement 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org.  
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Abstract 
Rationale: A potential adverse effect of high folate intake during pregnancy on children’s 
asthma development remains controversial. 
Objectives: To prospectively investigate folate intake from both food and supplements during 
pregnancy and asthma at age seven years when the diagnosis is more reliable than at preschool 
age. 
Methods: This study included eligible children born 2002-2006 from the Norwegian Mother and 
Child Cohort Study, a population-based pregnancy cohort, linked to the Norwegian Prescription 
Database. Current asthma at age seven was defined by asthma medications dispensed at least 
twice in the year (1,901 cases, n=39,846) or by maternal questionnaire report (1,624 cases, 
n=28,872). Maternal folate intake was assessed with a food frequency questionnaire validated 
against plasma folate. We used log-binomial and multinomial regression to calculate adjusted 
relative risks with 95% confidence intervals. 
Measurements and Main Results: Risk of asthma was increased in the highest vs. lowest 
quintile of total folate intake with an adjusted relative risk of 1.23 (95% confidence interval 1.06 
to 1.44) that was similar for maternally reported asthma. Mothers in the highest quintile had a 
relatively high intake of food folate (median 308, interquartile range 241-366 µg/day) and nearly 
all took at least 400 µg/day of supplemental folic acid (median 500, interquartile range 400-600). 
Conclusions: In this large prospective population based cohort with essentially complete follow-
up, pregnant women taking supplemental folic-acid at or above the recommended dose, 
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combined with a diet rich in folate, reach a total folate intake level associated with a slightly 
increased risk of asthma in children.  
Word count: 249 
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Introduction 
Nutrition in pregnancy plays a key role in fetal growth and development and may impact the 
long-term health of children (1). The importance of adequate folate status for preventing neural 
tube defects (2), has led to the current World Health Organization (WHO) recommendation that 
women should take a folic acid supplement of 400 micrograms per day (µg/day) from the time of 
planning a pregnancy until 12 weeks gestation. To better target women of reproductive age in the 
population as a whole, mandatory folic acid food fortification has been implemented in some 
countries, including the United States, and is currently under consideration in Europe (3). 
Although folic acid food fortification and supplementation during pregnancy at these levels are 
considered safe (2), there are concerns about unintended consequences (4). 
Several birth cohort studies have examined the association between maternal folate exposure 
during pregnancy and subsequent risk of children’s respiratory diseases. This literature has been 
summarized, in several reviews, as conflicting, with limitations due to heterogeneity in 
classification of folate intake, the time periods considered for exposure and disease development, 
and outcome definitions (5-8). Two more recent studies reported associations between asthma in 
children over four years of age and the use of folic acid supplements containing 1,000 µg or 
more during pregnancy (9, 10). This dose coincides with, or exceeds, the upper tolerable limit for 
daily folic acid intake in adults set by the US Institute of Medicine (11). 
We previously reported that use of folic acid supplements or higher maternal plasma folate levels 
in pregnancy was associated with increased risk of wheeze and respiratory tract infections up to 
18 months (12) and asthma at three years of age (13) from the Norwegian Mother and Child 
Cohort Study (MoBa).  
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The objective of the current study was to investigate the association between maternal total folate 
intake during pregnancy and asthma in MoBa children who have reached age seven years, an age 
when the asthma diagnosis is more reliable than at preschool age. Norway offers advantages for 
the assessment of folate intake from foods because very few foods are fortified with folic acid.  
The primary analysis of asthma at age seven years was based on prescription registry data 
enabling near complete follow-up of the cohort. We performed secondary analyses using 
maternal report of asthma and atopy on the questionnaire mailed at age seven years for 
comparison with our main results and to evaluate whether associations with asthma differed by 
current atopy.  
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Methods  
See online data supplement for more detail. 
Study population 
MoBa (14, 15) is a population-based pregnancy cohort (95,248 mothers and 114,761 children 
born 1999-2009), linked to the Norwegian birth registry and Norwegian Prescription Database 
(follow-up to April 1st 2014). Asthma at age seven years was defined in eligible children (sample 
selection and eligibility criteria, which included reaching the required age, in Figure 1) by 
prescription data (n=39,846, cases 1,901) or maternal report (n=28,872, cases 1,624). Both 
samples included births from 2002 to 2006 and partially overlapped (n=23,199). Maternal 
plasma folate was available for a random sample of children born 2002-2003 (16): 2,724 with 
maternal FFQ data (validation sample) and 2,681 with prescription follow-up and covariate 
information for an exploratory asthma analysis. 
Measures of maternal folate intake and folate status 
Total folate intake (expressed as folic acid equivalents or dietary folate equivalents (DFEs) (11) 
included food folate and folic acid from supplements, estimated from a validated food frequency 
questionnaire (FFQ) administered at about 22 weeks gestation (17, 18). Maternal plasma folate 
concentrations were measured (19) at Bevital AS laboratories (www.bevital.no) in a single non-
fasting venous blood sample drawn around 18 weeks gestation. 
Outcome measures of children’s asthma and atopy 
In separate analyses we examined current asthma in children around age seven using either at 
least two pharmacy dispensations of asthma medications (inhaled β2–agonists, inhaled 
glucocorticoids, combination inhalers with β2-agonists and glucocorticoids, and leukotriene 
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receptor antagonists) or maternal report of the child ever having doctor-verified asthma plus 
either asthma symptoms or asthma medication use in the past year (listing a valid brand). From 
maternal reports of the child’s eczema or allergy to either pollen or animal hair (cat or dog) with 
symptoms in the past year we created four mutually exclusive outcome groups: “atopy only”, 
“asthma only”, “asthma with atopy”, and “neither”(reference).  
Covariates 
Potential confounders and other covariates evaluated (Table 1) were based on data from the birth 
registry (maternal age at delivery, parity, child’s sex, and birth weight) or MoBa questionnaires 
completed around gestational weeks 18 (baseline) and 30, and when the child was aged 6 or 18 
months.  
Statistical analysis 
We used log binomial regression or multinomial logistic regression with robust cluster variance 
estimation to calculate relative risks (RRs) with confidence intervals (95% CIs) for children’s 
asthma. The covariates adjusted for are listed in the footnotes of Tables 2 and 3. In sensitivity 
analyses we additionally adjusted for the child’s birth weight (potential mediator), birth year and 
season, or postnatal child exposures at 6-18 months (duration of breast feeding, dietary 
supplement intake, and postnatal maternal smoking). Covariates were categorized as shown in 
Table 1 and entered as dummy variables, except for maternal age and energy intake (both 
continuous). We tested for multiplicative interaction between total folate intake and pre-
pregnancy BMI, maternal history of atopy, and smoking. Missing values in covariates were 
handled by multiple imputation (10 imputations using chained equations). The statistical 
significance level was 5% for all tests. The analyses were conducted in Stata 13.0 (StataCorp LP, 
Texas, USA).  
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Results 
Characteristics of the two main study samples (prescription registry sample and maternal report 
sample) and the validation subsample compared with those eligible for analysis, are shown in 
Table E1 (online data supplement). In the larger prescription registry sample, 57.6% of children 
(22,957/39,846) had a mother who reported any folic acid supplement use in pregnancy. Among 
women who took folic acid, the median intake from supplements alone was 400 (interquartile 
range (IQR) 200-414) µg/day. Among all women, the median intake of folate from food sources 
was 257 (IQR 205-321) µg/day. In the validation subsample (n=2,724), the plasma folate 
concentration (median 8.7, IQR 5.9-14.7) increased across quintiles of total folate intake 
(medians 6.5, 6.9, 8.8, 11.2 and 16.0 nmol/L for quintiles 1-5 in order, Table E2, online data 
supplement) and the overall Spearman correlation (continuous) was 0.45. 
Women in the highest quintile of total folate intake tended to be older, lighter, and less likely to 
smoke. They were also more likely to be primiparous, atopic, take other dietary supplements and 
were more highly educated (Table 1). Children born to mothers in the highest quintile of total 
folate intake were more likely to have been breastfed for at least 6 months and to have received 
dietary supplements at 6 and 18 months (Table 1). Patterns were similar in the maternal report 
sample (data not shown). All patterns held for quartiles of maternal plasma folate (results not 
shown), with the exception of a lack of association with maternal atopy. Plasma folate was also 
associated with gestational week of sample collection. 
The prevalence of current asthma at age seven years based on prescription registry data was 
4.8% (1,901/39,846). Children born to women in the highest vs. lowest quintile of total folate 
intake during pregnancy had more frequent asthma. In the highest quintile of pregnancy intake 
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5.6% (449/8,032) of children had been dispensed asthma medications at age seven compared 
with 4.6% (363/7,869) in the lowest (Table 2). The relative risk after multivariable adjustment 
was 23% higher in the highest versus lowest quintile (Table 2). The secondary analysis of asthma 
by maternal report gave similar results (Table E3, online data supplement).  
Sensitivity analyses are presented in Table E4 (online data supplement). Results were robust to 
adjustment for the child’s birth weight, or birth year and season, or postnatal childhood 
exposures. As expected, results were virtually identical for total folate expressed in folic acid 
equivalents and in dietary folate equivalents. Because some other studies have examined use of 
higher dose supplements, we divided the top quintile into three categories: 579-799, 800-999, 
and ≥1,000 µg (folic acid equivalents). Within the top quintile, risk did not increase with higher 
intakes, but data was sparse in the upper category (Table E4, online data supplement). In the 
much smaller plasma folate sample there was no significant association with asthma or elevated 
risk in the highest category (Table E5, online data supplement).  
Among children with current asthma at age seven defined by maternal report, 45% of cases 
(729/1,624) also had current atopy (Table 3). Compared with a reference category of neither 
asthma nor atopy, children born to mothers in the highest vs. lowest quintile of total folate intake 
during pregnancy had a higher relative risk of asthma only (33% increase) and asthma with atopy 
(51% increase). Although the p-value for trend across quintiles of folate intake was strongest for 
asthma with atopy, contrast analysis on the relative risks (highest vs. lowest quintiles) did not 
show statistically significant differences (p=0.49 for asthma with atopy vs. asthma only, and 
p=0.09 for asthma with atopy vs. atopy only, complete case analysis, n=27,369).  
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In stratified analyses (Table E6, online data supplement) results did not differ significantly 
according to pre-pregnancy BMI (pinteraction=0.22), maternal atopy (pinteraction=0.37) or maternal 
smoking (pinteraction=0.35). We examined the effect of food folate separately in users and nonusers 
of folic acid supplements and did not find a significant difference between groups 
(pinteraction=0.20).  
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Discussion 
In this population-based pregnancy cohort study, we observed a positive association between 
total folate intake during pregnancy and asthma at age seven in the offspring. Children born to 
women in the highest vs. lowest quintile of total folate intake during pregnancy had about 20% 
higher relative risk of asthma. Essentially all women in the highest quintile of total intake 
reported folic acid supplement use and took at least 400 µg/day of folic acid (Table E2, online 
data supplement) with many taking more; the median supplement intake was 500 µg/day, 25% 
above the 400 µg/day recommended both by the Norwegian government and the WHO. Women 
in the highest quintile of total intake, in addition to being supplement users, tended to have 
higher intakes from food sources; their median intake was 308 µg/day, nearly the cutpoint for the 
highest quintile of dietary folate intake.  
In previous analyses of younger MoBa children we observed associations between maternal use 
of folic acid supplements and wheezing and lower respiratory illness up to 18 months of age 
(12). In a sample of 1,962 children with maternal plasma folate measurements during pregnancy 
we observed a positive association with asthma at age three years (13). The current report 
extends these findings on maternal folate exposure to school age when asthma is more reliably 
diagnosed and also includes evaluation of asthma with and without atopic illness. 
Limitations and strengths of this study 
As in other large nationwide population based studies, we were not able to classify asthma based 
on clinical examination. Likewise we classified atopy based on questionnaire report of allergic 
conditions, limited to eczema and two aeroallergens, and some misclassification in our outcome 
measures cannot be ruled out. Another limitation of our study, as in any observational study, is 
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that we cannot exclude the possibility of residual or unmeasured confounding. Women who take 
folic acid supplements and have diets higher in folate might differ from other women in ways 
related to unknown causes of asthma, or health care utilization. Although we cannot exclude this 
possibility, Norway offers advantages because of the universal access to health care, both during 
pregnancy and childhood, and prescription medication coverage, coupled with a relatively 
narrow range of income variability. The objection could be raised that the association we are 
ascribing to folate could be due to correlated micronutrients from dietary supplements (21). 
However, adjustment for the common use of cod liver oil in Norway and other supplements, 
including multivitamins, had little impact on the results. 
Our study has several strengths. We used a validated FFQ to estimate total folate intake from 
both food and supplements. Many previous studies have examined only supplement use or 
separately considered diet and supplements. Total folate intake from our FFQ correlated well 
with plasma folate. Because there was virtually no fortification with folic acid in Norway in the 
study period our estimation of intake of folate from foods was simplified and therefore possibly 
more accurate than folate estimates from populations consuming fortified foods. In addition, we 
had a large sample size (1,901 cases) providing good power to study asthma at school age. We 
also had data on a large number of potential confounders including postnatal child exposures.  
Our primary outcome of asthma was defined by the filling of two prescriptions for asthma 
medications within a 12 month period. This is an objective outcome, requiring physician 
diagnosis. In a validation study of the MoBa seven year questionnaire items regarding asthma, 
we have found that even a single dispensing of asthma medication was very rare in the absence 
of the mothers report of doctor diagnosis of asthma (22). The requirement for a second 
prescription within 12 months in the current study decreases the possibility that the medication is 
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being prescribed for self-limited wheezing illness after a viral infection or as part of an 
evaluation to determine the child’s symptoms response to asthma medication. By requiring two 
prescriptions we expect a higher positive predictive value which has been reported to be the most 
important property of an asthma definition when the goal is to estimate relative risks as in our 
study (23). In addition to the validation in our own MoBa study population (22), an earlier 
validation study in Sweden, with a similar health care system to Norway, concluded that asthma 
medication is a suitable proxy for asthma in older children and adults based on comparison of 
data from their prescription registry and national patient registries (24). 
The use of this objective outcome also addresses potential selection bias caused by loss to 
follow-up at age seven years based on failure to return the questionnaire at this age because the 
prescription registry covers the entire population. Similar associations for asthma by maternal 
report and prescription data indicate that loss to follow-up had little influence. As expected, the 
prevalence of asthma at age seven years based on two dispensations of asthma medication 
(4.8%) is slightly lower than the reported national prevalence of around 6% for only one 
dispensation among children aged 6-12 years (25), but quite similar, suggesting little selection 
with regard to asthma among MoBa participants. Further, the prevalence among those eligible 
for the current study was the same as in study participants (Table E1, online data supplement). 
Comparison with other studies and potential mechanism 
The current study is the largest to date that examines total folate intake during pregnancy in 
relation to children’s asthma at school age. The total folate intake in these Norwegian women is 
very similar to that of women of reproductive age in the US, which practices mandatory folic 
acid food fortification. Specifically, the median total folate intake in dietary folate equivalents 
(Table E1, online data supplement) was 482 versus 490 reported for nonpregnant women aged 
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19-30 years in the US NHANES study from 2003-2006 (26). Two recent studies reported 20-
40% increased risk of asthma at school age (4.5 to 8 years) associated with dispensing of high 
dose maternal folic acid supplements: 1,000 µg in the study of Veeranki et al. (9) and 5,000 µg in 
the study of Zetstra-van der Woude et al. (10). Our study suggests that a lower intake of total 
folate is associated with increased risk of asthma. We only observed an increased risk in the top 
quintile, which could suggest a threshold effect. This level of intake (≥578 µg/day of folic acid 
equivalents) can be reached by taking the WHO recommended dose of 400 µg folic acid 
combined with either a multivitamin containing folic acid or at least 300 µg/day of food folate. 
Four prospective studies of childhood asthma at school age (5 to 8 years), have examined folic 
acid supplement use during pregnancy without finding an association (27-30); sizes ranged from 
130 to 605 cases. Thus, differences may be due in part to the greater power in the current study 
with 1,901 cases. However, because these studies did not include a measure of total folate intake, 
from both foods and supplements, their null findings may not be in conflict with ours. The US 
study (30) recruited pregnant women from 1997 to 2000, mostly after folic acid food fortification 
was implemented. Thus, the folate intake among the reference group of women, who did not take 
folic acid supplements, could already be above a threshold where risk of asthma does not 
increase much further. Of note, a US study found no evidence for protection against neural tube 
defects from folic acid supplement use in pregnancy and interpreted this result as evidence that 
fortification had already increased intake sufficiently to prevent these birth defects (31).  
Studies with null results from European countries without mandatory folic acid fortification of 
the food supply (27-29) only analyzed food folate or folic acid supplements, but not the 
combined intake, and thus may not have identified the pregnancies with the highest total intake 
of folate. Two previous studies of children’s asthma at school age used FFQs to assess folate 
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intake amounts from food and supplements, as in our study, during pregnancy (32, 33). Nwaru et 
al. (32) studied children at age five years in Finland and found no association of total folate 
intake with asthma. Although the dietary folate intake was relatively high (mean 364 µg/day), the 
folic acid intake from supplements was very low (mean 48 µg/day). In contrast, the Australian 
study population of Withrow et al. (33) took higher dose folic acid supplements during early 
pregnancy (median 658 µg/day) and increased risks of asthma at age 3.5 years, and persistent 
asthma at ages 3.5 and 5.5 years were observed.  
Few studies to date have investigated maternal circulating folate levels in relation to asthma in 
school age children. Magdelijns et al. (28) reported a tendency of an inverse association between 
red blood cell folate in late pregnancy (week 35) and asthma risk at age six to seven years 
(n=837, 43 cases in total). The lack of association with plasma folate in the current study likely 
reflects the much lower statistical power in the plasma subsample with only 127 cases compared 
with 1,901 in the primary analysis of folate intake and 507 cases in our previous case-control 
study of asthma at age three (13). Very large studies with measurements of red blood cell folate, 
which reflects longer term status than plasma folate, may be necessary to more definitely answer 
the question of whether maternal folate status in the first trimester is associated with children’s 
asthma development, because other lifestyle factors, metabolism and genetics all can affect folate 
levels in addition to intake. 
Folate (natural or as synthetic folic acid) provides, with vitamin B12 as cofactor, methyl groups 
for the synthesis of methionine and S-adenosyl-methionine, which acts as a methyl donor (4). 
Epigenetic modification, more specifically DNA methylation, provides one potential mechanism 
for an effect of in utero exposures to folate and other methyl donors on the offspring (34). 
Although it did not address relevance to asthma, a recent study identified differential methylation 
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at various loci in newborns in relation to maternal folate levels in pregnancy (35). In an Agouti 
mouse model, supplementation of mothers with folate and other methyl donors just before and 
during gestation and during lactation, abrogated effects of an environmental contaminant 
(bisphenol-A) on methylation in offspring (36). Interest in this mechanism with respect to asthma 
was stimulated by the report of Hollingsworth et al. in 2008 (34) that in utero supplementation 
with methyl donors in pregnant mice, altered locus-specific DNA methylation and predisposed to 
allergic airway disease by directing the differentiation of T lymphocytes toward a TH2 
phenotype. One of the top differentially methylated loci, RUNX3, in a previous knock out mouse 
model (37), displayed an allergic asthma phenotype. However, this paper was recently retracted 
because of problems with the airway hyperresponsiveness data; the other data in the paper were 
not affected (38). We acknowledge that the mechanistic data on periconceptional folate, or other 
methyl donors, and asthma pathogenesis is very limited. 
Folic acid supplementation during pregnancy has an established role in the prevention of neural 
tube defects but the mechanism of this protection remains largely unknown (2). Two MoBa 
studies have found the use of folic acid supplements during pregnancy to protect against other 
neurological outcomes including language delay (39) and autism spectrum disorders (40). Taken 
together with our results, these findings point towards multiple folate-dependent pathways in the 
fetus of importance to development of neurologic and immune systems. 
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Conclusion 
In this large prospective pregnancy cohort, pregnant women taking folic-acid containing 
supplements at or above the recommended dose, combined with a diet rich in folate, reach a total 
folate intake level that was associated with a slightly increased asthma risk in children. We note 
that increased risk of asthma was only seen in the highest quintile of intake in which women also 
had a generally folate rich diet. In populations with very low folate intake, women taking the 
WHO recommended dose of folic acid may not reach this level of intake. On the other end of the 
spectrum, the specific associations might not be observable in populations where mandatory folic 
acid food fortification has already been implemented.  
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Figure legends 
Figure 1 Sample selection 







Full MoBa cohort, Version 8 
n=114,761 children 
(from 112,773 pregnancies)  
Singleton children alive and residing in 
Norway, born to mothers with pregnancy FFQ 
data and plausible energy intake 
n=83,203 (dyads) 
No maternal food frequency questionnaire 
(FFQ) data (n=16,275) 
Early version of FFQ (births 1999-2002) 
covering diet only before pregnancy (n=9,087) 
Energy intake <4,500 or > 20,000 kJ (n=1,464) 
Eligible for analysis of asthma and atopy 
based on maternal report  
(n=52,579) 
Eligible for analysis of asthma based on 
Norwegian Prescription Database 
(n=41,777) 
No baseline questionnaire at 18 weeks 
gestation (n=260) 
No questionnaire at 30 weeks gestation 
(n=1,966) 
No questionnaire at 7 years  
(n=21,481) 
Children too young for having 
prescription follow-up to age 8 years by 
April 1
st
 2014 (n=41,426) 
No linkage to birth registry (n=257) 
Non-live births (n=377) 
Multiple births (n=3,179) 
Later child death or emigration (n=919) 
Analysis of asthma and atopy based on 
maternal questionnaire report in relation to 
total maternal folate intake in pregnancy, 
n=28,872 
Analysis of asthma based on Norwegian 
Prescription Database in relation to total 
maternal folate intake in pregnancy, 
n=39,846 
No maternal baseline questionnaire at 18 
weeks gestation (n=132) 
No maternal questionnaire at 30 weeks 
gestation (n=1,799) 
Children too young for having the 7 year 
questionnaire sent/processed by 
December 31
st
, 2013 (n=30,624) 
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Table 1 Distribution of maternal and child characteristics according to total maternal folate 
intake in pregnancy, by quintiles (n=39,846) 













N 7,869 8,046 7,981 7,918 8,032 
Mean maternal age at delivery, years 29.8 30.1 30.0 30.0 30.2 
No. of previous children (%)      
 0 36.4 37.9 43.5 47.1 52.0 
 1 39.5 36.9 34.3 35.2 32.5 
≥2 24.1 25.2 22.2 17.7 15.5 
Maternal education* (%)      
Less than high school 11.8 9.9 9.4 6.3 5.5 
High school 38.0 33.7 32.9 27.7 28.1 
Up to 4 years of college 36.7 38.9 40.0 44.8 44.7 
More than 4 years of college 13.5 17.5 17.7 21.2 21.6 
Maternal pre-pregnancy BMI*, kg/m2 
(%)  
    
<18.5 2.2 2.6 3.1 2.7 3.0 
18.5-24.9 59.0 63.5 65.1 65.4 67.0 
25.0-29.9 25.4 24.3 21.7 22.8 21.2 
≥30 13.3 9.6 10.1 9.2 8.7 
Mean maternal energy intake (kJ/day) 8,150 10,174 10,680 9,387 10,439 
Maternal history of atopy (% Yes) 31.1 30.5 33.2 34.4 36.8 
Cod liver oil taken in pregnancy 
(% Yes) 
29.5 36.6 39.0 44.0 46.3 
Other supplements taken in pregnancy† 
(% Yes)  
34.7 40.6 65.1 61.6 79.2 
Maternal smoking in pregnancy* 
(% Yes) 
12.8 10.6 10.1 7.1 7.0 
Postnatal maternal smoking at 18 
months* (% Sometimes/daily) 20.3 17.6 17.7 13.7 14.3 
Child’s sex (% Boys) 52.3 51.0 50.7 50.3 50.7 
Child’s birth weight*, grams (%)       
<2,500 2.6 2.6 2.7 2.6 2.6 
2,500-4,500 92.6 92.6 92.7 93.0 92.7 
>4,500 4.8 4.8 4.6 4.4 4.7 
Any breast feeding ≥ 6 months duration 
(% Yes) 80.5 84.3 84.0 86.0 86.2 
Child given supplements at 6 months† 
(% Yes)  
56.2 60.8 62.3 61.8 64.5 
Child given supplements at 18 months† 
(% Yes)  
68.9 72.5 76.9 76.8 80.6 
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Pearson’s chi2 p-value ≤0.001 for all associations except with child’s sex (p=0.1) and birth 
weight (p=0.98). 
*Missing values: from <0.05% (birth weight) to 20% (child supplements at 18 months) as 
indicated in Table E1 (online data supplement). 
†Other supplements taken in pregnancy contains at least one of the vitamins B2, B6, B12, C, A, 
D, and E. Children’s supplements include cod liver oil and/or liquid multivitamins.  
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Table 2 Crude and adjusted relative risk (RR) estimates (95% confidence interval) for current 
asthma at age 7 years based on the Norwegian Prescription Database, by quintiles of total 
maternal folate intake in pregnancy (n=39,846) 
Total folate*  Cases/total 
(n) 
Crude RR Adjusted RR† 
Q1  363/7,869 1.00 (ref) 1.00 (ref) 
Q2  351/8,046 0.95 (0.82,1.09) 0.97 (0.83,1.13) 
Q3  393/7,981 1.07 (0.93,1.23) 1.07 (0.92,1.24) 
Q4  345/7,918 0.94 (0.82.1.09) 0.98 (0.85,1.14) 
Q5  449/8,032 1.21 (1.06,1.39) 1.23 (1.06,1.44) 
ptrend   0.01 0.01 
*Quintile limits for total folate intake from food and supplements (folic acid equivalents, 
µg/day): Q1 (≤146), Q2 (147-216), Q3 (217-391), Q4 (392-577), Q5 (≥578). 
†Adjusted for maternal age at delivery (continuous), parity (0, 1, ≥2), maternal education (less 
than high school, high school, up to 4 years of college, more than 4 years of college), pre-
pregnancy BMI (<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2), maternal history of atopy (no, yes), 
maternal smoking in pregnancy (no, yes), and use of cod liver oil (no, yes), other dietary 
supplements (no, yes), and maternal energy intake (continuous) in pregnancy. Missing values in 
covariates (Table E1, online data supplement) handled by multiple imputation (m=10) using 
chained equations. 
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Table 3 Crude and adjusted multinomial logistic regression relative risk (RR) estimates (95% confidence interval) for current asthma 
and/or current atopy at age 7 years based on maternal questionnaire report by quintiles of total maternal folate intake in pregnancy 
(n=28,872) 




 Current atopy only 
n=4,460 
 Current asthma only 
n=895 

















































































ptrend     0.001 0.11   0.03 0.02   <0.0001 <0.0001 
*Quintile limits for total folate intake from food and supplements (folic acid equivalents, µg/day): Q1 (≤146), Q2 (147-216), Q3 (217-
391), Q4 (392-577), Q5 (≥578). 
†Adjusted for maternal age at delivery (continuous), parity (0, 1, ≥2), maternal education (less than high school, high school, up to 4 
years of college, more than 4 years of college), pre-pregnancy BMI (<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2), maternal history of 
atopy (no, yes), maternal smoking in pregnancy (no, yes), and use of cod liver oil (no, yes), other dietary supplements (no, yes), and 
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maternal energy intake (continuous) in pregnancy. Missing values in covariates (Table E1, online data supplement) handled by 
multiple imputation (m=10) using chained equations. 
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Unabridged methods section 
Study population 
We used data from MoBa, a population-based prospective pregnancy cohort administered by 
the Norwegian Institute of Public Health (1, 2). MoBa recruited pregnant women nationwide 
between 1999 and 2008 at approximately 18 weeks gestation. Mothers could participate with 
more than one pregnancy, resulting in 95,248 mothers and 114,761 children born 1999-2009. 
The follow-up of children is ongoing through postal questionnaires and registry linkages 
using the national 11-digit personal identification number. 
For the current study we analyzed MoBa data with linkage to two national health registries: 
the Norwegian birth registry and the Norwegian Prescription Database (henceforth referred to 
as the “prescription registry”, end of follow-up April 1
st
 2014). The primary analysis of 
asthma at age seven years was based on prescription registry data (n=39,846, 1901 cases), 
which enabled near complete follow-up of the cohort to limit potential selection bias. In a 
secondary analysis we used maternal questionnaire report (n=28,872, cases 1,624). The 
sample selection and eligibility criteria are shown in Figure 1. 
To define asthma using the prescription registry, children had to be old enough to have 
prescription data recorded 12 months past age seven years. This definition required longer 
follow-up (to eight years) than asthma based on maternal report at age seven years, but the 
prescription registry sample was larger because the follow-up was near complete. Both study 
samples included births from 2002 to 2006 and partially overlapped (n=23,199). Of the 
prescription registry sample 42% had no follow-up through the 7-year questionnaire; of the 
maternal report sample 20% were younger than eight years by the end of prescription follow-
up.  
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Maternal plasma folate was available for a random sample of children born 2002-2003 (3): 
2,724 with maternal FFQ data (validation sample) and 2,681 with prescription follow-up and 
covariate information for an exploratory asthma analysis. 
Ethical approval 
All participants in MoBa gave written informed consent at the time of enrolment. The 
Norwegian Data Inspectorate approved the ongoing data collection in MoBa (reference 
number 01/4325-69/HTL), and the linkage between MoBa and the Norwegian Prescription 
Database (reference number 08/00854-2/IUR). Ethical approval was obtained by the Regional 
Committee for Medical and Health Research Ethics of South/East Norway (reference number 
2011/2313b). 
Exposure measures of maternal folate intake 
Maternal total folate intake included folate from foods and folic acid from supplements, 
estimated from a validated food frequency questionnaire (FFQ) administered at about 22 
weeks gestation (4, 5). Starting in 2002, women reported their intake since becoming 
pregnant. Folic acid supplement use was defined as folic acid intake >0 µg/day from any 
supplement (folic acid only, multivitamin, or other). Total folate was expressed in µg of folic 
acid equivalents using the established conversion factor of 0.6 × food folate + supplemental 
folic acid (6). For comparability with some other studies we also calculated total folate in 
dietary folate equivalents (DFEs) as food folate + 1.7 × supplemental folic acid. Subject 
classification into quintiles of total folate intake was almost identical for folic acid equivalents 
and dietary folate equivalents (>99% agreement).  
Exposure measure of maternal folate status in mid-pregnancy 
A single non-fasting venous blood sample was drawn from mothers (median 18, interquartile 
range 17-19 gestational weeks) at a routine ultrasound examination offered to all pregnant 
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women, and processed as previously described (2). Plasma was mailed at ambient temperature 
to the MoBa biobank and stored at −80°C until analysis at Bevital AS laboratories 
(www.bevital.no). The plasma folate concentration was measured by microbiological assay 
(Lactobacillus casei) (7). The within- and between day coefficients of variation are 4% and 
5% respectively and the lower limit of detection (LOD) is 2.0 nmol/L. 
Outcome measures of children’s asthma and atopy 
Our primary asthma outcome was registry based and required that the child had at least two 
pharmacy dispensations of asthma medications in a year (at least one dispensation in the past 
12 months at seven years in addition to a second dispensation within 12 months of the first). 
The ascertainment period was 12 months for all eligible children. The medication groups and 
Anatomical Therapeutic Chemical (ATC) classification codes included were inhaled β2–
agonists (R03AC), inhaled glucocorticoids (R03BA), combination inhalers with β2-agonists 
and glucocorticoids (R03AK), and leukotriene receptor antagonists (R03DC). The active 
substances in each medication group are listed elsewhere (8). Noncases were all children who 
did not meet the criteria of having at least two dispensations of these medications around age 
seven.  
As a secondary outcome we used maternal report of asthma on the follow-up questionnaire 
when the child was seven years old. The mother had to confirm all of the following: her child 
ever having asthma verified by a doctor and, in addition, either asthma symptoms or asthma 
medication use in the past year (listing at least one brand). Noncases were children with no 
asthma verified by a doctor regardless of symptoms or medication use.   
To evaluate whether associations differed by the presence of atopy, we used a surrogate 
measure based on maternal report on the seven year questionnaire of the child’s eczema or 
allergy to either pollen or animal hair (cat or dog) with symptoms in the past year. Using this 
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surrogate for atopy, we created four mutually exclusive groups: “atopy only”, “asthma only”, 
“asthma with atopy”, and “neither” (reference).  
Covariates 
Potential confounders and other covariates evaluated in the analysis (Table 1) were identified 
a priori based on the literature (9-11) or included for consistency with our previous study 
results (12-14). Variables were based on data from the birth registry (maternal age at delivery, 
parity, child’s sex, and birth weight) or MoBa questionnaires completed at about gestational 
weeks 18 (baseline) and 30, and when the child was aged 6 or 18 months. Maternal history of 
atopy was defined as ever reported asthma, allergy to pollen, animal hair, or “other” allergy, 
or atopic dermatitis. “Other” dietary supplements taken in pregnancy included supplements 
other than folic acid and cod liver oil that contained at least one of the vitamins B2, B6, B12, 
C, A, D, and E. Children’s supplement intake included cod liver oil and liquid multivitamins. 
Because the majority of Norwegian women breastfeed and have more than six months 
maternity leave, we dichotomized any breast feeding into two categories based on duration 
using a cutpoint of 6 months. Maternal smoking during pregnancy or at 18 months was treated 
as yes versus no because most women who smoked reported low amounts of smoking 
(median (interquartile range) = 5 (1-8) cigarettes per day during pregnancy and 10 (5-10) at 
18 months). Gestational week of sample collection (categorized as ≤16, 17, 18, 19, ≥20 
weeks) was included as a covariate in the analysis of maternal plasma folate. 
Statistical analysis 
We used log binomial regression to calculate relative risks (RRs) for children’s asthma in 
relation to quintiles of maternal total folate intake. Maternal plasma folate levels were 
analyzed as quartiles using a similar approach as for total folate intake. 
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For asthma with atopy we used multinomial logistic regression. Confidence intervals (95% 
CIs) were derived by robust cluster variance estimation to account for correlation between 
siblings. All adjusted models included the following prenatal maternal factors showing a 
univariate association with both exposure and outcome (confounders by classical definition): 
age at delivery, parity, education, pre-pregnancy BMI, smoking in pregnancy, history of 
atopy, and use of cod liver oil, other supplements (containing at least one of the vitamins B2, 
B6, B12, C, A, D, or E), and energy intake in pregnancy. In sensitivity analyses we 
additionally adjusted for the child’s birth weight as a potential mediator, or birth year and 
season (January-March, April-June, July-September, October-December), or postnatal child 
exposures (duration of breastfeeding, supplement intake at 6 months and 18 months, and 
maternal smoking at 18 months). Covariates were categorized as shown in Table 1 and 
entered as dummy variables, except for maternal age and energy intake (both continuous). We 
tested for multiplicative interaction between total folate intake (highest vs. all lower quintiles) 
and the following variables: pre-pregnancy BMI (≥ 25 vs < 25 kg/m
2
) (15), maternal history 
of atopy (no/yes) and smoking. Missing values in covariates were handled by multiple 
imputation using chained equations to generate 10 datasets. The statistical significance level 
was 5% for all tests. The analyses were conducted in Stata 13.0 (StataCorp LP, Texas, USA).  
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E1: Distribution of maternal and child characteristics among eligible participants and study 
samples in the Norwegian Mother and Child Cohort Study
 
 
Asthma based on Norwegian 
Prescription Database  







 Eligible Study 
sample 
N 41,777 39,846 2,724  52,579 28,872 
Maternal age at delivery, years (%)       
<25 11.6 11.3 12.1  11.3 8.7 
25-30 42.6 42.8 43.9  42.4 41.8 
>30 45.8 45.9 44.0  46.3 49.5 
No. of previous children (%)       
  0 43.2 43.4 41.2  43.9 44.2 
  1 35.8 35.7 37.7  35.9 36.0 
≥2 21.1 20.9 21.1  20.1 19.8 
Maternal education
 
(%)       
Less than high school 8.9 8.6 8.9  8.2 5.8 
High school 31.9 31.9 35.4  30.9 27.9 
Up to 4 years of college 40.4 40.9 38.8  40.6 44.3 
More than 4 years of college 18.1 18.2 16.6  19.4 21.7 
Missing 0.7 0.4 0.4  0.9 0.3 




     
 
<18.5 2.8 2.7 2.5  2.8 2.5 
18.5-24.9 61.9 62.2 62.4  62.1 64.3 
25.0-29.9 22.3 22.4 20.9  22.1 22.0 
≥30 9.8 9.9 10.6  9.8 8.8 
Missing 3.3 2.9 3.5  3.3 2.4 
Maternal history of atopy (%)       
No 66.7 66.8 67.3  66.2 66.3 
Yes 33.0 33.2 32.7  33.3 33.7 
Missing 0.3 0.0 0.0  0.5 0.0 
Cod liver oil taken in pregnancy (%)       
No 58.1 60.9 61.6  57.6 58.0 
Yes 37.3 39.1 38.4  38.2 42.0 
Missing 4.6 0.0 0.0  4.2 0.0 
Other supplements taken in 
pregnancy (%)  
     
 
No 41.7 43.7 48.3  41.3 41.5 
Yes 53.7 56.3 51.7  54.5 58.5 
Missing 4.6 0.0 0.0  4.2 0.0 
Maternal smoking in pregnancy (%)       
No 89.5 90.1 87.1  90.1 92.8 
Yes 9.8 9.5 12.2  8.9 6.7 
Missing 0.8 0.4 0.7  1.0 0.5 
Child’s sex (% boys) 51.1 51.0 50.9  51.1 51.3 
Child’s birth weight, grams
 
(%)        
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 Asthma based on Norwegian 
Prescription Database  







 Eligible Study 
sample 
<2,500 2.9 2.6 2.1  2.7 2.6 
2,500-4,500 92.4 92.7 92.8  92.7 92.9 
>4,500 4.7 4.7 5.2  4.5 4.5 
Missing 0.04 0.04 0.0  0.04 0.03 
Birth season       
Jan-Mar 23.6 23.6 21.4  23.3 24.0 
Apr-Jun 21.9 21.9 7.3  24.5 25.0 
Jul-Sep 28.5 28.4 27.4  28.9 28.9 
Oct-Dec 26.0 26.0 43.9  23.2 22.1 
Birth year       
2002 10.2 10.1 50.7  7.6 8.0 
2003 27.0 26.9 49.3  21.0 20.7 
2004 28.6 28.5 -  22.4 22.9 
2005 31.0 31.3 -  24.5 24.7 
2006 3.1 3.2 -  24.5 23.7 
Duration of any breast feeding (%)       
< 6 months 15.6 15.8 15.9  15.3 14.8 
≥ 6 months 84.4 84.2 84.1  84.7 85.2 
Child given supplements at 6 months
 
(%) 
     
 
No 34.9 35.7 32.0  36.0 38.3 
Yes 54.9 56.3 60.4  53.8 59.0 
Missing 10.2 8.0 7.6  10.2 2.7 




     
 
No 19.3 19.9 19.2  19.8 22.8 
Yes 58.6 60.4 61.5  57.5 68.8 
Missing 22.1 19.7 19.3  22.7 8.4 




   
 
No 64.3 66.3 63.1  64.2 77.8 
Sometimes/daily 12.9 13.2 16.6  12.3 13.1 
Missing 22.8 20.5 20.3  23.5 9.2 
Folate exposures from food 
frequency questionnaire at about 
22 weeks of pregnancy 
      
Food folate, median (µg/day) 258 257 255  259 258 
Folic acid from supplements in users 
only, median (µg/day) 
400 400 400  400 400 
Folic acid supplement use (%)       
No 41.6 41.3 44.8  40.7 38.5 
Yes 57.2 57.6 53.9  58.2 60.7 
Missing 1.2 1.1 1.3  1.1 0.8 
Total folate as folic acid 
equivalents
*
, median (µg /day) 
284 287 251  295 319 
Total folate as dietary folate 477 482 421  495 536 
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 Asthma based on Norwegian 
Prescription Database  














Food folate assumed to be 60% bioavailable relative to folic acid from supplements in the 
calculation of folic acid equivalents and dietary folate equivalents (DFE). Maternal folic acid 
supplement intake was missing for 0.8-1.1% in the study samples and only food folate was 
included in total folate intake.  
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Table E2: Relationship between quintiles (Q1 to Q5) of total folate intake, food folate, folic 
acid from supplements, and plasma folate during pregnancy in the study sample based on the 
Norwegian Prescription Database (n=39,846) 













N 7,869 8,046 7,981 7,918 8,032 
Median (interquartile range) 
FFQ intake  
    










Supplemental folic acid 



























% Contribution of folic 










































% Folic acid supplement 
use (n=39,403) 
4 16 70 99 >99 
Median (interquartile range) 













Food folate assumed to be 60% bioavailable relative to folic acid from supplements in the 
calculation of folic acid equivalents and dietary folate equivalents (DFE). Maternal folic acid 
supplement intake was missing for n=443 and only food folate was included in total folate 
intake. 
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Table E3: Crude and adjusted relative risk (RR) estimates (95% confidence interval) for 
children having current asthma at age 7 years based on the Norwegian Prescription Database 
compared with maternal questionnaire report, by quintiles (Q1 to Q5) of total folate intake 
(diet and supplements) in pregnancy 
   Prescription database 
N=39,846 






Crude RR Adj RR†  Cases/total 
(n) 
Crude RR Adj RR† 
Q1  363/7,869 1.00 (ref) 1.00 (ref)  276/5224 1.00 (ref) 1.00 (ref) 
































ptrend   0.01 0.01   <0.0001 <0.0001 
*
Food folate assumed to be 60% bioavailable relative to folic acid from supplements in the 
calculation of folic acid equivalents. Maternal folic acid supplement intake was missing for 
n=443 and only food folate was included in total folate intake. Quintile limits for total folate 
intake (folic acid equivalents, µg /day): Q1 (≤146), Q2 (147-216), Q3 (217-391), Q4 (392-
577), Q5 (≥ 578). 
†
Adjusted for maternal age at delivery (continuous), parity (0, 1, ≥2), maternal education (less 
than high school, high school, up to 4 years of college, more than 4 years of college), pre-
pregnancy BMI (<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m
2
), maternal history of atopy (no, yes), 
maternal smoking in pregnancy (no, yes), and use of cod liver oil (no, yes), other dietary 
supplements (no, yes), and maternal energy intake (continuous) in pregnancy. 
Missing values in covariates (Web Table 1) handled by multiple imputation (m=10) using 
chained equations. 
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Table E4: Sensitivity analysis of adjusted relative risk (RR) estimates (95% confidence interval) for children having current asthma at age 7 years 


























Main model + 















































































ptrend  0.01 0.01 0.03 0.01 0.01 0.007 0.01 
Splitting Q5         
578-799 350/6,248  1.24 
(1.06,1.46) 
     
800-999 68/1,126  1.30 
(1.00,1.68) 
     
≥ 1,000 31/658  1.03 
(0.71,1.48) 
     
*
Food folate assumed to be 60% bioavailable relative to folic acid from supplements in the calculation of folic acid equivalents and dietary folate 
equivalents (DFE). Maternal folic acid supplement intake was missing for n=443 and only food folate was included in total folate intake. Quintile 
limits for DFEs: Q1 (≤245), Q2 (246-361), Q3 (362-659), Q4 (660-976), Q5 (≥ 977). 
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†
Adjusted for all factors listed in Table 1 (related to exposure and/or outcome): maternal age at delivery (continuous), parity (0, 1, ≥2), maternal 
education (less than high school, high school, up to 4 years of college, more than 4 years of college), pre-pregnancy BMI (<18.5, 18.5-24.9, 25.0-
29.9, ≥30 kg/m
2
), maternal energy intake (continuous, kj/day), maternal history of atopy (no, yes), use of cod liver oil (no, yes) and other dietary 
supplements (no, yes) in pregnancy, maternal smoking in pregnancy (no, yes), child’s sex, child’s birth weight (<2500, 2500-4500, >4500 
grams), duration of any breast feeding (< 6 months, ≥ 6 months), dietary supplements given at 6 months (no, yes) and 18 months (no, yes), and 
postnatal maternal smoking at 18 months (no, sometimes/daily). 
‡
Main model is adjusted for maternal characteristics and prenatal factors related to both exposure and outcome: age at delivery (continuous), 
parity (0, 1, ≥2), maternal education (less than high school, high school, up to 4 years of college, more than 4 years of college), pre-pregnancy 
BMI (<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m
2
), maternal history of atopy (no, yes), maternal smoking in pregnancy (no, yes), and use of cod liver 
oil (no, yes) and other dietary supplements (no, yes) in pregnancy. Additional adjustment for maternal energy intake (continuous, kJ/day). 
Complete cases include the subsample with complete data for all covariates (n=38,398). 
§
Child’s birth weight categorized as: <2500, 2500-4500, >4500 grams. Birth years 2002 to 2006 (categorical) and birth season (Jan-Mar, Apr-
Jun, Jul-Sep, Oct-Dec). Postnatal child exposures: duration of any breast feeding (< 6 months, ≥ 6 months), dietary supplement intake at 6 
months (no, yes) and 18 months (no, yes), postnatal maternal smoking at 18 months (no, sometimes/daily). 
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Table E5: Crude and adjusted relative risk (RR) estimates (95% confidence interval) for 
children having current asthma at age 7 years based on the Norwegian Prescription Database, 
by quartiles (Q1-Q4) of maternal plasma folate concentrations in mid-pregnancy (n=2,681) 
Plasma folate (nmol/L) Cases/total 
(n) 
Crude RR Adj. RR
* 
















ptrend  0.44 0.99 
*
Adjusted for maternal age at delivery (continuous), parity (0, 1, ≥2) maternal education (less 
than high school, high school, up to 4 years of college, more than 4 years of college), pre-
pregnancy BMI (continuous), maternal history of atopy (no, yes), maternal smoking in 
pregnancy (no, yes), use of cod liver oil (no, yes) and other dietary supplements (no, yes) in 
pregnancy, and gestational week of sample collection (≤16, 17, 18, 19, ≥20 weeks). 
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Table E6: Stratified multivariable relative risk (RR) estimates (95% confidence interval) for 
children having current asthma at age 7 years based on the Norwegian Prescription Database 























      



















39 11   
Pinteraction   0.22 0.20 
Maternal history of atopy      
No 
(n=26,613) 










Pinteraction    0.36 0.41 
Smoking in pregnancy      
No 
(n=35,894) 












6 1    
Pinteraction    0.37 0.66 
Food folate
*
      
Folic acid supplement use    n=39,846 n=37,989 
No 
(n=16,446) 












11 7    
Pinteraction    0.20  0.24 
*Upper quintile limit for total folate intake (folic acid equivalents, µg/day): Q5 (≥ 578). 
Upper quintile limit for food folate (µg/day): Q5 (≥ 308). 
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†
Adjusted for maternal age at delivery (continuous), parity (0, 1, ≥2), maternal education (less 
than high school, high school, up to 4 years of college, more than 4 years of college), pre-
pregnancy BMI (<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2), maternal history of atopy (no, yes), 
maternal smoking in pregnancy (no, yes), use of cod liver oil (no, yes) and other dietary 
supplements (no, yes) in pregnancy, and maternal energy intake (continuous). 
Missing values in stratification variables and other covariates handled by multiple imputation 
(m=10) using chained equations.  
Complete cases include the subsample with complete data for all covariates (n=38,398) or for 
all covariates and folic acid supplement use (n=37,989).  
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